Perioperative antiplatelet therapy: A knife-edged choice between thrombosis and bleeding still based on consensus rather than evidence

Thrombosis and Haemostasis

Volumn 105, Issue 5, 2011, Pages 750-751

  Peter, Karlheinz ^a,b   Myles, Paul S ^a,b  

^a ALFRED HOSPITAL   (Australia)

^b MONASH UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; CLOPIDOGREL;

ANTICOAGULANT THERAPY; BLEEDING; CARDIOVASCULAR RISK; CLINICAL TRIAL (TOPIC); CONSENSUS DEVELOPMENT; CORONARY ARTERY BYPASS GRAFT; CORONARY ARTERY DISEASE; DRUG EFFICACY; DRUG POTENCY; DRUG SAFETY; DRUG WITHDRAWAL; EDITORIAL; EVIDENCE BASED PRACTICE; HEART INFARCTION; HIGH RISK PATIENT; HUMAN; LOW DRUG DOSE; MEDICAL DECISION MAKING; PATIENT COMPLIANCE; PERIOPERATIVE PERIOD; PRACTICE GUIDELINE; PRIMARY PREVENTION; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS; RISK REDUCTION; SECONDARY PREVENTION; SHEAR STRESS; STENT THROMBOSIS; THROMBOSIS;

EID: 79955762714     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH11-02-0124     Document Type: Editorial

References (24)

1. Weiser TG, et al. An estimation of the global volume of surgery: a modelling strategy based on available data. Lancet 2008; 372: 139-144.
2. Devereaux PJ, et al. Perioperative cardiac events in patients undergoing noncardiac surgery: a review of the magnitude of the problem, the pathophysiology of the events and methods to estimate and communicate risk. CMAJ 2005; 173: 627-634.
3. Korte W, et al. Peri-operative management of antiplatelet therapy in patients with coronary artery disease. Thromb Haemost 2011; 105: 743-749.
4. Oscarsson A, et al. To continue or discontinue aspirin in the perioperative period: a randomized, controlled clinical trial. Br J Anaesth 2010; 104: 305-312.
5. Straub A, et al. Critical temperature ranges of hypothermia-induced platelet activation: possible implications for cooling patients in cardiac surgery. Thromb Haemost 2007; 97: 608-616.
6. von Kanel R, et al. Effect of beta2-adrenergic receptor functioning and increased norepinephrine on the hypercoagulable state with mental stress. Am Heart J 2002; 144: 68-72.
7. Priebe HJ. Triggers of perioperative myocardial ischaemia and infarction. Br J Anaesth 2004; 93: 9-20.
8. Naesh O, et al. Platelet function in surgical stress. Thromb Haemost 1985; 54: 849-852.
9. Beving H, et al. Abnormally high platelet activity after discontinuation of acetylsalicylic acid treatment. Blood Coagul Fibrinolysis 1996; 7: 80-84.
10. Ferrari E, et al. Coronary syndromes following aspirin withdrawal: a special risk for late stent thrombosis. J Am Coll Cardiol 2005; 45: 456-459.
11. Biondi-Zoccai GG, et al. A systematic review and meta-analysis on the hazards of discontinuing or not adhering to aspirin among 50,279 patients at risk for coronary artery disease. Eur Heart J 2006; 27: 2667-2674.
12. Chassot PG, et al. Perioperative antiplatelet therapy: the case for continuing therapy in patients at risk of myocardial infarction. Br J Anaesth 2007; 99: 316-328.
13. Sun JC, et al. The effect of pre-operative aspirin on bleeding, transfusion, myocardial infarction, and mortality in coronary artery bypass surgery: a systematic review of randomized and observational studies. Eur Heart J 2008; 29: 1057-1071.
14. Burger W, et al. Low-dose aspirin for secondary cardiovascular prevention-cardiovascular risks after its perioperative withdrawal versus bleeding risks with its continuation-review and meta-analysis. J Intern Med 2005; 257: 399-414.
15. Vicenzi MN, et al. Coronary artery stenting and non-cardiac surgery--a prospective outcome study. Br J Anaesth 2006; 96: 686-693.
16. Newsome LT, et al. Coronary artery stents: II. Perioperative considerations and management. Anesth Analg 2008; 107: 570-590.
17. Gasparyan AY, et al. The role of aspirin in cardiovascular prevention: implications of aspirin resistance. J Am Coll Cardiol 2008; 51: 1829-1843.
18. Buchanan MR, Brister SJ. Individual variation in the effects of ASA on platelet function: implications for the use of ASA clinically. Can J Cardiol 1995; 11: 221-227.
19. Zimmermann N, Hohlfeld T. Clinical implications of aspirin resistance. Thromb Haemost 2008; 100: 379-390.
20. Zimmermann N, et al. Aspirin resistance after coronary artery bypass grafting. J Thorac Cardiovasc Surg 2001; 121: 982-984.
21. Cornelissen J, et al. Biological efficacy of low against medium dose aspirin regimen after coronary surgery: analysis of platelet function. Thromb Haemost 2006; 95: 476-482.
22. Santilli F, et al. Platelet cyclooxygenase inhibition by low-dose aspirin is not reflected consistently by platelet function assays: implications for aspirin ″resistance″. J Am Coll Cardiol 2009; 53: 667-677.
23. Zurn CS, et al. ADP-receptor blockade: A case for personalised pharmacotherapy? Thromb Haemost 2010; 103: 496-506.
24. Becker RC, Gurbel PA. Platelet P2Y12 receptor antagonist pharmacokinetics and pharmacodynamics: A foundation for distinguishing mechanisms of bleeding and anticipated risk for plateletdirected therapies. Thromb Haemost 2010; 103: 535-544.